Celltrion announced on November 10 that it achieved sales of KRW 401 billion won (US$340 million), operating profit of KRW 164 billion won (US$140 million), and an operating profit margin of 40.9% in the third quarter.
Due to the unexpectedly surge in demand in the United States, the supply of Remsima is expanding, and Truxima's market share is continuing to grow.
However, the delay in sales of TEVA migraine treatment to 4Q and the increase in sales of Remsima, which has a relatively low unit price compared to other products, contributed to the decrease in sales and operating profit compared to the same period last year.
Operating profit margin reached 40.9% thanks to an increase in the sales portion of highly efficient Korean products due to the rapid growth of Remsima's market share in the US, and the expansion of Truxima's solid market share.
"Major biosimilar products are still growing stably in the European market, and Remsima's market share in the US is increasing significantly, so we expect continued and solid growth going forward," said a Celltrion official.
"Celltrion will accelerate its commercialization with differentiated marketability compared to competing products by rapidly proceeding with global clinical trials to expand the next-generation biosimilar pipeline as planned," he added. "The company will do its best to proceed with the global approval process and supply of Regkirona and COVID-19 diagnostic kits without any setbacks."
